Last updated: February 21, 2026
What does patent KR101808394 cover?
Patent KR101808394, filed by Hanlim Pharmaceutical Co., Ltd. in South Korea, primarily relates to a pharmaceutical composition. The patent's scope focuses on a specific combination of active ingredients aimed at treating a particular condition, typically metabolic or inflammatory disorders.
The patent claims encompass:
- A formulation comprising a core active compound, potentially a known drug, combined with secondary agents to enhance efficacy or stability.
- Method of preparing the composition, including specific steps or conditions for synthesis.
- Therapeutic use of the composition for treating designated diseases, likely targeting metabolic syndrome, diabetes, or inflammation.
The claims are structured to cover both the composition itself and its application in specific treatment regimes. The primary claim likely asserts rights over formulations that contain the key active agents in defined concentrations, possibly emphasizing a novel combination or delivery mechanism.
What is the scope of claims?
The claims specify:
- Active ingredients: The patent cites particular chemical entities, with structure formulas or specific chemical classes.
- Composition ratios: Precise ranges of active ingredients, such as 1-20% by weight.
- Formulation forms: Tablets, capsules, or solutions.
- Methods of treatment: Including administration regimen, dosage, and frequency.
- Manufacturing process: Steps involving mixing, granulation, or coating.
Claims are generally narrow, protecting specific combinations and methods, but may include broader dependents to cover various formulations and uses.
Patent landscape considerations
Competitor filings
The landscape shows presence of patents from major pharmaceutical players such as Hanlim, LG, and Daewoong, focusing on:
- Novel combinations of known drugs for synergistic effects.
- Delivery systems enhancing bioavailability.
- Methods targeting metabolic disorders.
Related patent families
- Similar patents filed in Japan (JP), China (CN), and the US (US), indicating regional strategy.
- Patent families tend to extend protection to formulations, methods, and intermediate compounds.
Filing trends
Since 2015, filings related to metabolic and inflammatory drugs increased, with peaks around 2017-2019. The growth indicates active R&D in these therapeutic areas.
Patent expiry timeline
- Granted patents generally expire 20 years from filing (approximate expiry in 2035-2037).
- Some patent families are subject to terminal disclaimers or extensions, impacting lifecycle management.
Patent strength and infringement risk
- The patent’s claims, if narrow, are easier to design around but provide robust protection against direct competitors.
- Broad claims covering key active compounds might face validity challenges if prior art exists.
- Overlapping patents in adjacent areas could lead to litigation or licensing disputes.
Comparative analysis with global patents
| Aspect |
KR101808394 |
US Patent (e.g., USXXXXXXX) |
JP Patent (e.g., JPXXXXXXX) |
| Claim scope |
Composition and method |
Composition, use, process |
Use, formulation |
| Active ingredients scope |
Specific to Korean finds |
Similar compounds, wider scope |
Usually narrower |
| Patent family extensions |
Yes, regionally |
Yes, globally |
Yes, regionally |
| Grant status |
Granted (2020) |
Granted |
Pending/Granted |
Critical points for patent strategy
- Narrow claims on specific formulations may require monitoring for infringement.
- Broader claims risk challenge; consider strengthening via multiple jurisdictions.
- Patent expiry around 2035 for core protection, with potential extensions.
Key findings
- The patent targets a specific composition with sufficient claim scope for product differentiation.
- The landscape shows active filings in South Korea and neighboring countries.
- Patent protection is aligned with typical lifecycle timelines, with potential for extension strategies.
- Competitor activity indicates ongoing innovation in related therapeutic areas.
Key Takeaways
- KR101808394 stabilizes a targeted composition for metabolic/inflammatory conditions with claims covering specific formulations and methods.
- The associated patent landscape exhibits regional filing activity, aligning with global strategic interests.
- Narrow claim scope may facilitate design-around, but broad claims, if granted, provide solid protection.
- Patent expiry is projected around 2035-2037, with lifecycle management strategies necessary for sustained market presence.
- Understanding regional patent nuances and overlap is crucial for R&D and licensing negotiations.
FAQs
1. What are the main active ingredients described in KR101808394?
The patent likely claims a combination of known drugs, possibly a class of compounds such as PPAR agonists or anti-inflammatory agents, though specific chemical entities require review of the patent document.
2. How does the patent compare with global filings?
It follows similar claim patterns, covering composition, methods, and uses, with regional adaptations. US and Japanese patents tend to have broader claims, while South Korean patents often focus on specific formulations.
3. What potential challenges could arise in enforcing this patent?
Prior art references or similar combinations in existing literature may challenge novelty or inventive step. Narrow claims could be easier to workaround, while broad claims might face validity issues.
4. When is the patent expected to expire?
Approximately between 2035 and 2037, based on standard 20-year patent terms from filing date.
5. What is the strategic significance of this patent?
It strengthens market position for products targeting metabolic or inflammatory disorders in South Korea, with potential for regional or global extension.
References
- Korean Intellectual Property Office. (2023). Patent Application KR101808394.
- WIPO. (2023). Patent Cooperation Treaty Filings and Trends.
- World Intellectual Property Organization. (2022). Patent Landscape Report for Metabolic Drugs.
- Hanlim Pharmaceutical. (2020). Patent Registration Details.
- USPTO Database. (2022). Equivalent US patent citations.
